NCT05015816Fut, nem toboroz
MoleGazer Development Feasibility Study
MoleGazer: A Feasibility Study for Early Detection of Melanoma
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. júl. 8.
Rövid összefoglaló (regiszter, angolul)
Melanoma (skin cancer) frequently develops from existing moles on the skin. Current practice relies on expert dermatologists being able to successfully identify new/changing moles in individuals with multiple moles. Total body photography (TBP-high-quality images of the entire skin) can track and monitor moles over time to detect melanoma. However, TBP is currently used as a visual guide when diagnosing melanoma, requiring visual inspection of each mole sequentially. This process is challenging, time-consuming and inefficient. Artificial intelligence (AI) is ideally suited to automate this process. Comparing baseline TBP images to newly acquired photographs, AI techniques can be used to accurately identify and highlight changing moles, and potentially distinguish harmless moles from cancerous changes. Astrophysicists face a similar problem when they map the night sky to detect new events, such as exploding stars. Using AI, based on two or more images, astrophysicists detect new events and accurately predict how they will appear subsequently. This project, called MoleGazer, is a collaboration with astrophysicists aiming to apply AI methods that are currently used for astronomical sky surveys, to TBP images. The MoleGazer algorithm, developed at Oxford University Hospitals NHS Foundation Trust, will automatically identify the appearance of new moles and characterise changes in existing ones, when new TBP images are taken. To optimise this MoleGazer algorithm TBP images will be taken at multiple time-points, as there are no existing datasets of TBP images that are publicly available. The investigators invite a) high-risk patients attending skin cancer screening clinics to attend sequential three-monthly TBP imaging and clinical assessment and b) any patient who undergoes TBP as standard care to share images so that the investigators can develop the MoleGazer algorithm. The ultimate goal is for the MoleGazer algorithm to 'map moles' over a patient's lifetime to detect changes, with the eventual aim to detect melanoma as early as possible.
- Állapot (regiszter)
- Fut, nem toboroz
- Vizsgálattípus
- Beavatkozással járó
- Résztvevők száma
- 374 (tényleges)
- Első benyújtás
- 2020. dec. 19.
- Kezdés
- 2021. szept. 13.
- Elsődleges befejezés
- 2024. febr. 28.
- Fő szponzor
- Oxford University Hospitals NHS Trust
- Betegségek
- Melanóma
- NCT-szám
- NCT05015816
Mit vállalsz
- Vizsgálat típusa: Beavatkozással járó
- Bevont résztvevők: 374
- 2021. szept. 13. és az elsődleges befejezés (2024. febr. 28.) között
- 1 helyszín, 1 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Korábbi kezelés
- Patient with active malignancy affecting any organ and receiving any cancer-specific treatment
Egyéb
- The participant may not enter the study if ANY of the following apply:
- Patient unable to consent
- Poor mobility / unable to hold recommended positions for standard TBP imaging
- Individuals who do not understand English
- In addition for Group A:
- ● Unable to attend for three-monthly study visits
Kiket keres a vizsgálat
- Participant is willing and able to give informed consent for participation in the study
- Male or Female, aged 18-80 years old
- In addition for Group A:
- Willing to attend for additional study visits and total body photography imaging
- High-risk melanoma patients including:
- Dysplastic / atypical naevus syndrome (> 60 moles +/- personal history of melanoma)
- Family history of melanoma
- Past history of at least two primary melanoma or melanoma-in situ
- At least 3 first-degree or second-degree relatives with prior melanoma
- CDKN2A or CDK4 germline mutation
- Individuals with multiple naevi (>25) who are immunosuppressed from any cause (e.g. organ transplant recipients, chronic lymphocytic leukaemia, etc.)
- In addition for Group B:
- ● Has previously had total body photography imaging OR will have total body photography as part of standard care
Életkor a regiszterben: 18 év – 80 év · Nem: nők és férfiak · Egészséges önkénteseket is fogad
Helyszínek (1)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| Churchill Hospital | Headington | Egyesült Királyság | Ismeretlen állapot |
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.